J. P. Sy

发表

A Stochastic Model for Analysis of Longitudinal AIDS Data

Jeremy M. G. Taylor, William G. Cumberland, J. P. Sy, 1994 .

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

J. P. Sy, H. Tiddens, J. Sy, 2001, The Journal of pediatrics.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Susan Schneider, Mark Michels, J. P. Sy, 2006, The New England journal of medicine.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Mark Michels, J. P. Sy, Peter K Kaiser, 2009, Ophthalmology.

Do growth hormone (GH) serial sampling, insulin‐like growth factor‐I (IGF‐I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?

J. P. Sy, J. Sy, A. Rogol, 2003, Clinical endocrinology.

Estimation in a Cox Proportional Hazards Cure Model

J. P. Sy, J. M. Taylor, J. Sy, 2000, Biometrics.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

J. P. Sy, P. Rosenfeld, R. Dreyer, 2006, Ophthalmology.

Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience.

J. P. Sy, J. Sy, D. Hardin, 1997, The Journal of pediatrics.

Identifiability of cure models

Chin-Shang Li, J. P. Sy, Chin-Shang Li, 2001 .